FLT3-ITD – Medxy AI

靶向线粒体复合体I亚基NDUFS2：提升FLT3-ITD急性髓系白血病对FLT3抑制剂的疗效

Enhancing FLT3 Inhibitor Efficacy in FLT3-ITD AML Through Targeting Mitochondrial Complex I Subunit NDUFS2

By MedXY 10/26/2026

Targeting the mitochondrial complex I subunit NDUFS2 enhances sensitivity to FLT3 inhibitors and overcomes drug resistance in acute myeloid leukemia with FLT3-ITD mutations, suggesting a promising therapeutic strategy.

老年新诊断AML患者中米哚妥林联合低剂量阿糖胞苷与维奈克拉：INTERVENE II期试验的证据与启示

Clinical Updates Hematology-Oncology news

Combining Midostaurin with Low-Dose Cytarabine and Venetoclax in Older Adults with Newly Diagnosed AML: Evidence and Implications from the INTERVENE Phase 2 Trial

By MedXY 10/25/2026

The INTERVENE trial reveals that adding midostaurin to low-dose cytarabine and venetoclax is tolerable and improves FLT3-ITD clearance and survival in older AML patients with FLT3-ITD, addressing resistance in this high-risk subgroup.

Hematology-Oncology news Pathology & Lab Medicine

ELN‑DAVID technical recommendations: NGS-based FLT3‑ITD MRD testing in AML — what clinicians and labs need to know

By MedXY 08/15/2026

The ELN‑DAVID 2026 technical note establishes standards for NGS-based detection of FLT3‑ITD measurable residual disease (MRD) in AML, with lab validation, reporting, timing, and clinical-use recommendations to make FLT3‑ITD MRD testing actionable in routine care.

Hematology-Oncology news

Unexpected Prognostic Significance of FLT3-ITD Microclones in Young Adults with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

By MedXY 08/05/2026

Low-level FLT3-ITD microclones, detected via NGS in young adults with AML, independently increase relapse risk comparable to macroclones, challenging current risk stratification and underscoring the need to integrate advanced genetic testing in clinical practice.

Hematology-Oncology news

Noncanonical FLT3-ITD Signaling Drives Immune Evasion via PKCι-STAT1–Mediated CD8+ T-Cell Exhaustion in Acute Myeloid Leukemia

By MedXY 07/15/2026

FLT3-ITD mutations in AML promote immune evasion through a novel PKCι–STAT1 signaling axis that induces CD276-mediated CD8+ T-cell exhaustion, offering a promising target for combined FLT3 and CD276-directed therapies.

Hematology-Oncology news Oncology

S1P Receptor Modulation Restores FLT3 Inhibitor Sensitivity in NRAS-Mutated FLT3-ITD Acute Myeloid Leukemia

By MedXY 06/04/2026

Preclinical data suggest fingolimod and mocravimod can resensitize NRAS-mutated FLT3-ITD AML to FLT3 inhibitors by suppressing ERK-SPHK1-AKT signaling, including activity in patient blasts and an orthotopic mouse model.

Hematology-Oncology news

Comprehensive Mutational Profiling and Clinical Outcomes in Adult AML with NUP98 Rearrangement

By MedXY 05/18/2026

Adult AML with NUP98 rearrangements is a high-risk subtype marked by frequent FLT3-ITD and WT1 mutations, poor survival, and potential benefit from FLT3 inhibitors and stem cell transplant.

Hematology-Oncology news Pediatrics

Allogeneic Stem Cell Transplantation Improves Survival in High-Risk t(6;9) AML, Especially in Younger Patients and Those Achieving CR1

By MedXY 04/27/2026

A large EBMT study shows allo-HSCT provides favorable 2-year survival (65.7%) in high-risk t(6;9) AML, with superior outcomes in CR1 and pediatric/AYA patients. FLT3-ITD positivity triples relapse risk but doesn't impact overall survival.

Hematology-Oncology news

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease

By MedXY 11/04/2025

Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.